Wool-anchored Pd(OAc)₂ complex: a highly active and reusable catalyst for

the desulfurative coupling reactions

SUPPORTING INFORMATION

Quanlu Yang,^{*a*, *b*} Zhengjun Quan,**^a* Baoxin Du,^{*a*} Shang Wu,^{*a*, *c*} Peidong Li,^{*b*} Yanxia Sun,^{*b*} Ziqiang Lei^{*a*} and Xicun Wang*^{*a*}

^a Laboratory of Eco-Environment-Related Polymer Materials, Ministry of Education; Key Laboratory of Polymer Materials, College of Chemistry and Chemical Engineering, Northwest Normal University, Lanzhou, Gansu 730070, P. R. China

wangxicun@nwnu.edu.cn

- ^b College of Chemical Engineering, Lanzhou University of Arts and Science, Beimiantan 400, Lanzhou, Gansu 730000, P. R. China
- ^c College of Chemical Engineering, Northwest University for Nationalities, Lanzhou, Gansu 730030, P. R. China

Contents

Table of contents	S 1
General	S2
Experimental details and characterization for catalyst and all compounds	S3 – S6
Referrences	S7
The NMR Data for the Products	S8 - S13
Copies of the NMR Spectra for New Products	S14 – S58

1. General

All reactions were conducted under a nitrogen atmosphere with a dual-manifold Schlenk tube, unless otherwise mentioned, and in oven-dried glassware. Gas chromatography (GC) analysis was performed on a Shimadezu GC-2010 equipped with a 15 m \times 0.53 mm \times 1.5 μ m RTX-1 capillary column and a oxyhydrogen flame detector. ICP-AES were measured on IRIS Advantage. XPS measurement was recorded on PHI5702 photoelectron spectrometer. Binding energy was referred to C_{1s} (284.80 eV). FTIR spectroscopy patterns were obtained on an FT/IR-660 Plus system (Jasco, Tokyo, Japan). The samples were mixed with KBr powders and pressed into a disk suitable for FTIR measurement. The morphologies of the catalyst were examined with field emission scanning electron microscopy (FE-SEM, Ultra Plus, Carl Zeiss). Elemental analysis of the photocatalyst was conducted by an energy-dispersive X-ray spectrometer (EDX) attached to the scanning electron microscope. ¹H NMR and ¹³C NMR data analyses were performed with a Varian Mercury plus-400 instrument unless otherwise specified. CDCl₃ as solvent and tetramethylsilane (TMS) as the internal standard were employed. Chemical shifts were reported in units (ppm) by assigning TMS resonance in the ¹H NMR spectrum as 0.00 ppm. The data of ¹H NMR was reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet and br = broad), coupling constant (J values) in Hz and integration. Chemical shift for ${}^{13}C$ NMR spectra were recorded in ppm from TMS using the central peak of CDCl₃ (77.0ppm) as the internal standard. Flash chromatography was performed using 200-300 mesh silica gel with the indicated solvent system according to standard techniques. Analytical thin-layer chromatography (TLC) was performed on pre-coated, glass-backed silica gel plates. Melting points were measured with an XT-4 apparatus. High-resolution mass spectra (HRMS) (ESI) were obtained with a Bruker Daltonics APEX II 47e and Orbitrap Elite mass spectrometer. Mass-spectra (EI) were recorded on a TRACE DSQ instrument. Column chromatography was generally performed on silica gel (200-300 mesh) and TLC analyses were conducted on silica gel GF254 plates. Palladium (II) acetate, alkynes, carboxylic acids, Cu₂O, P ligands and solvents were all purchased from J&K Scientific Ltd. All reagents were directly used from purchased without any further purification unless otherwise specified. Wool was provided by Gansu Jingyuan Woolen Mill (Jingyuan town, Gansu province, PR China).

2. Experimental details and characterization for catalyst and all compounds

2.1 The wool-anchored palladium(II) was prepared following these procedures: 1.0 g the treated-wool pieces prepared in our laboratory¹⁻⁵ (a, Figure 1) and 0.2 g Pd(OAc)₂ were dipped in 30 mL of de-ionized water, the mixture was stirred at r.t. for 3 h until the white wool pieces become to brownish yellow. Then the biomacromolecule-Pd(OAc)₂ complex catalyst was filtered and washed with de-ionized water(3×20 mL) and acetone (3×20 mL), dryed in a vacuum oven at 50 °C for 4 h. (b, Figure 1) The palladium content in Wool-Pd(II) complex was determined by means of inductively coupled plasma equipped with atomic emission spectrometry (ICP-AES) and amounted to be 1.56 wt %. The possible structure of wool-Pd(OAc)₂ complex was shown in Figure 2.



Figure 1. (a) Wool fibre, and (b) wool-Pd(OAc)₂ complex.



Figure 2. The possible structure of wool-Pd(OAc)₂ complex.

2.2 General procedures for preparation of substrates 1a (eq. S1).⁶ The substrates **1a** was synthesized through the reactions between DHPM and phenylboronic acid. DHPM (90.6 mg; 0.33 mmol), PhB(OH)₂ (121.9 mg; 1 mmol), phenanthroline (118.9 mg; 0.66 mmol), Cu(OAc)₂ (59.9 mg; 0.33 mmol), 4\AA molecularsieves powder (250 mg) and 1,2-dichlorethane (5 ml) were added into a reaction vessel. The mixture was stired for 4 days and then transferred to a round bottom flask, and was adsorbed on silica gel.

The residue was purified by flash chromatography on silica gel.



2.3 General procedures for preparation of substrates 7 (eq. S2).⁷ The substrates 7 were synthesized through the reactions between disulfides and Grignard reagent. Under argon atmosphere, disulfide (1 mmol), ferrocene (5 mol%) were added into a Schlenk tube dried by Hot-gun. The tube was stopped and degassed with argon for three times. Then EtMgBr (5 mmol), THF (6 mL) were added by syringe. The mixture was stirred under argon atmosphere at -20 °C for 0.5 h. Then 1 mL water was added to quench the reaction, and the organic components were extracted by acetic ether and evaporated in vacuum and further purified by column chromatography on silica gel.



2.4 General procedures for the domino process (eq. S4). Under argon atmosphere, 1a (0.25 mmol, 69 mg), wool-Pd(OAc)₂ (10 mg, Pd 1.56 wt %), Cu₂O (0.25 mmol, 36 mg), DPE-Phos (5 μ mol, 2.5 mg, 2 mol%) were added into a Schlenk tube dried by Hot-gun. The tube was stopped and degassed with argon for three times. Then 2a (0.50 mmol, 30 mg), 3a (0.375 mmol, 38 mg) and dioxane (2 mL) were added by syringe. The mixture was stirred under argon atmosphere at 110°C for 48 h. Then the mixture was cooled down to room temperature with 2 mL saturated solution of NH₄Cl added to quench the reaction and 1 mL dilute solution of NaOH to neutralize the excess 2a. Then, the organic components were extracted by acetic ether and evaporated in vacuum and further purified by column chromatography on silica gel with petroleum ether/ethanol (60:1) to give the product 4a (89 mg, 88%) as yellow solid.



2.5 General procedures for the Sonogashira reactions between 2-(ethylthio)pyrimidine derivatives and terminal alkynes (eq. S5). Under argon atmosphere, 7a (0.25 mmol, 75 mg), wool-Pd(OAc)₂ (10 mg, Pd 1.56 wt %), CuTC (0.50 mmol, 95 mg), DPE-Phos (5 μ mol, 2.5 mg, 2 mol%) were added into a Schlenk tube dried by Hot-gun. The tube was stopped and degassed with argon for three times. Then 3a (0.50 mmol, 51 mg) and dioxane (2 mL) were added by syringe. The mixture was stirred under argon atmosphere at 110°C for 48 h. Then the mixture was cooled down to room temperature with 2 mL saturated solution of NH₄Cl added to quench the reaction and 1 mL dilute solution of NaOH to neutralize the excess acid. Then, the organic components were extracted by acetic ether and evaporated in vacuum and further purified by column chromatography on silica gel with petroleum ether/ethanol (60:1) to give the product 8a (68 mg, 79%) as clear solid.



2.6 General procedures for the reaction between 2-(phenylthio)-1,4-dihydropyrimidine derivatives and arylboronic acids (eq. S6). Under argon atmosphere, 1a (0.25 mmol, 69 mg), 8a (0.50 mmol, 61 mg), wool-Pd(OAc)₂ (10 mg, Pd 1.56 wt %), CuTC (0.50 mmol, 95 mg), DPE-Phos (5 μ mol, 2.5 mg, 2 mol%) were added into a Schlenk tube dried by Hot-gun. The tube was stopped and degassed with argon for three times. Then dioxane (2 mL) was added by syringe. The mixture was stirred under argon atmosphere at 110°C for 24 h. Then the mixture was cooled down to room temperature with 2 mL saturated solution of NH₄Cl added to quench the reaction and 1 mL dilute solution of NaOH to neutralize the excess acid. Then, the organic components were extracted by acetic ether and evaporated in vacuum and further purified by column chromatography on silica gel with petroleum ether/ethanol (60:1) to give the product 10a (53 mg, 65%) as yellow oil.



2.7 General procedures for the reaction between 2-(ethylthio)pyrimidine derivatives and arylboronic acids (eq. S7). Under argon atmosphere, 7a (0.25 mmol, 30 mg), 8a (0.50 mmol, 61 mg), wool-Pd(OAc)₂ (10 mg, Pd 1.56 wt %), CuTC (0.50 mmol, 95 mg), DPE-Phos (5 μ mol, 2.5 mg, 2 mol%) were added into a Schlenk tube dried by Hot-gun. The tube was stopped and degassed with argon for three times. Then dioxane (2 mL) was added by syringe. The mixture was stirred under argon atmosphere at 110°C for 24 h. Then the mixture was cooled down to room temperature with 2 mL saturated solution of NH₄Cl added to quench the reaction and 1 mL dilute solution of NaOH to neutralize the excess acid. Then, the organic components were extracted by acetic ether and evaporated in vacuum and further purified by column chromatography on silica gel with petroleum ether/ethanol (60:1) to give the product **11a** (65 mg, 82%) as clear solid.



2.8 Procedures for the hot-filtration test.

The hot-filtration test was carried out with an investigation upon the reactions among 1a, 2a and 3a. Two parallel reactions were undertaken under the identical standard conditions we use (see Part 2.5 above in this chapter). In one reaction, the mixture was quickly hot filtered with a Teflon syringe filter (0.2 mm pore size) after 12 h of reaction. The conversion of 1a was immediately detected by HPLC (a conversion of 41%). The other reaction system was not intervened. Both reaction was continued thereafter for another 36 h and then quenched. The conversion of 1a was detected by HPLC. As a result, the reaction that was handled by the hot-filtration remained the conversion of 41%; and the other reaction reached a conversion of 88%.

2.9 Procedures for the recycling test.

After the reactions among **1a**, **2a** and **3a**, the wool-Pd(OAc)₂ complex was filtrated, and washed with deionized water ($3 \times 10 \text{ mL}$) and acetone ($3 \times 10 \text{ mL}$), dried in a vacuum oven at 50 °C. Then it was used in a new round of the cycle, with new substrates and additives added. The catalyst was reused repeatedly for nine times and then was examined by ICP-AES analysis within very narrow scope (1.56% to 1.43%) to observe its palladium content. The total TON value is 1320. Only 68 parts per billion palladium was detected in the reaction phase, (ICP-MS) indicating quite a slender metal leaching of the catalyst during the reactions. Also, throughout the recycled tests of nine rounds, the yields of product **4a** were not declined all the while

Referrences

- 1. S. Wu, H. C. Ma, X. J. Jia, Y. M. Zhong, Z. Q. Lei, Tetrahedron, 2011, 67, 250.
- 2. H. C. Ma, W. Cao, Z. K. Bao, Z. Q. Lei, Catal. Sci. Technol., 2012, 2, 2291.
- 3. H. C. Ma, F. Wang, W. Cao, Z. K. Bao, Y. Ma, Z. W. Yang, Z. Q. Lei, Chin. J. Catal., 2012, 33, 1594.
- 4. Q. Z. Wang, J. J. Li, N. An, Y. Bai, X. L. Lu, J. Li, H. C. Ma, R. F. Wang, F. P. Wang, Z. Q. Lei, W. F. Shangguan, *Int. J. Hydrogen Energ.*, 2013, **38**, 10761.
- Q. Z. Wang, J. J. Li, Y. Bai, X. L. Lu, Y. M. Ding, S. Q. Yin, H. H. Huang, H. C. Ma, F. P. Wang, B. T. Su, J. Photoch. Photobio. B, 2013, 126, 47.
- 6. A. Lengar, C. O. Kappe, Org. Lett. 2004, 6, 771.
- 7. B. X. Du, Z. J. Quan, Y. X. Da, Z. Zhang, X. C. Wang, Adv. Synth. Catal., 2015, 357, 1270.

The NMR Data for the Products

(E)-ethyl 3-acetyl-6-methyl-2-(2-oxo-2-phenylethylidene)-4-phenyl-1,2,3,4-tetrahydro- pyrimidine-5carboxylate (4a) Yellow solid (89 mg, 88%); m.p. = 197°C. ¹H NMR (400 MHz, CDCl₃): δ = 1.26 (t, *J* = 7.2Hz, 3H), 2.55 (s, 3H), 2.58 (s, 3H), 4.18-4.23 (q, 2H), 6.00 (s, 1H), 6.70 (s, 1H), 7.25-7.32 (m, 5H), 7.42-7.51 (m, 3H), 7.84 (d, *J* = 7.2Hz, 2H), 12.78 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.26, 18.64, 24.61 52.15, 60.44, 90.88, 106.68, 126.92, 127.24, 128.04, 128.56, 128.67, 132.06, 138.95, 139.01, 144.28, 150.48, 165.17, 169.58, 189.25 ppm.

(E)-ethyl 3-acetyl-4-(2-methoxyphenyl)-6-methyl-2-(2-oxo-2-phenylethylidene)-1,2,3,4tetrahydropyrimidine-5-carboxylate (4b) Yellow solid (61 mg, 56%); m.p. = $165 \sim 166^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.23$ (t, J = 7.2Hz, 3H), 2.53 (s, 3H), 2.54 (s, 3H), 3.79 (s, 3H), 4.16-4.19 (m, 2H), 6.24 (s, 1H), 6.66 (s, 1H), 6.84-6.87 (m, 2H), 7.17-7.28 (m, 2H), 7.38-7.42 (m, 3H), 7.84 (d, J = 7.2Hz, 2H), 12.86 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.17$, 18.55, 24.15, 50.39, 55.11, 60.17, 91.27, 105.29, 111.00, 120.39, 125.89, 127.19, 128.35, 128.92, 129.58, 131.71, 139.17, 144.34, 150.28, 157.41, 165.15, 169.64, 189.58 ppm.

(E)-ethyl 3-acetyl-6-methyl-4-(4-nitrophenyl)-2-(2-oxo-2-phenylethylidene)-1,2,3,4tetrahydropyrimidine-5-carboxylate (4c) Yellow solid (86 mg, 77%); m.p. = $178 \sim 179^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.23$ (t, J = 7.2Hz, 3H), 2.53 (s, 3H), 2.56 (s, 3H), 4.15-4.20 (q, 2H), 5.90 (s, 1H), 6.65 (s, 1H), 6.96 (t, J = 8.8Hz, 2H), 7.26-7.50 (m, 5H), 7.81-7.83 (m, 2H), 12.74 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.15$, 18.53, 24.48, 51.38, 60.38, 90.83, 106.46, 115.36, 115.57, 127.14, 128.71, 128.80, 132.06, 138.75, 144.22, 150.17, 164.93, 169.41, 189.18 ppm.

(E)-ethyl 3-acetyl-4-(2-chlorophenyl)-6-methyl-2-(2-oxo-2-phenylethylidene)-1,2,3,4tetrahydropyrimidine-5-carboxylate (4d) Yellow solid (67 mg, 61%); m.p. = $222\sim223^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): δ = 1.23 (s, 3H), 2.48 (d, *J* = 1.2Hz, 3H), 2.58 (s, 3H), 4.13-4.16 (q, 2H), 5.98 (d, *J* = 1.2Hz, 1H), 7.04 (s, 1H), 7.18 (s, 3H), 7.37-7.50 (m, 4H), 7.83 (d, *J* = 6.0Hz, 2H), 12.59 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.12, 18.45, 24.07, 49.73, 60.35, 92.95, 107.00, 127.04, 127.24, 128.49, 128.85, 129.51, 130.40, 132.15, 135.66, 138.61, 144.52, 150.02, 164.73, 168.53, 189.49 ppm.

(E)-ethyl 3-hexanoyl-6-methyl-2-(2-oxohexylidene)-4-phenyl-1,2,3,4-tetrahydro- pyrimidine-5carboxylate (4e) Yellow oil (75 mg, 74%). ¹H NMR (400 MHz, CDCl₃): $\delta = 0.89$ (s, 6H), 1.22 (t, J = 6.8Hz, 3H), 1.32 (s, 6H), 1.55-1.58 (m, 2H), 1.72-1.74 (m, 2H), 2.30-2.40 (m, 2H), 2.48 (s, 3H), 2.71 (s, 2H), 2.13-2.18 (q, 2H), 5.31 (s, 1H), 6.59 (s, 1H), 7.25 (s, 5H), 12.27 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 13.67$, 14.01, 18.34, 22.17, 25.45, 27.37, 31.14, 35.83, 42.63, 51.76, 60.05, 93.54, 105.76, 126.65, 127.63, 128.32, 139.04, 144.30, 148.47, 165.01, 172.69, 200.05 ppm.

(E)-ethyl 6-methyl-2-(2-oxo-2-phenylethylidene)-4-phenyl-3-(thiophene-2-carbonyl)-1,2,3,4tetrahydropyrimidine-5-carboxylate (4f) Yellow solid (80 mg, 68%), m.p. = $157 \sim 158$ °C. ¹H NMR (400 MHz, CDCl₃): = 1.27 (t, J = 8.0 Hz, 3H), 2.62 (s, 3H), 4.20 (q, J = 8.0 Hz, 2H), 5.71 (s, 1H), 6.45 (s, 1H), 7.01-7.08 (m, 1H), 7.27-7.60 (m, 12H), 12.72 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.24$, 18.86, 54.81, 60.49, 92.66, 106.89, 127.08, 127.43, 128.27, 128.37, 128.88, 131.84, 132.11, 132.46, 136.91, 138.91, 139.26, 144.35, 151.50, 163.16, 165.05, 188.75 ppm.

(E)-ethyl 3-(furan-2-carbonyl)-6-methyl-2-(2-oxo-2-phenylethylidene)-4-phenyl-1,2,3,4tetrahydropyrimidine-5-carboxylate (4g) Yellow solid (74 mg, 65%), m.p. = $159\sim160$ °C. ¹H NMR (400 MHz, CDCl₃): = 1.27 (t, J = 8.0 Hz, 3H), 2.68 (s, 3H), 4.21 (q, J = 8.0 Hz, 2H), 5.50 (s, 1H), 6.45 (s, 1H), 6.55-6.60 (m, 1H), 7.27–7.55 (m, 12H), 12.70 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.26$, 18.81, 54.31, 60.45, 90.50, 106.62, 112.25, 118.78, 127.02, 127.22, 128.12, 128.35, 128.61, 131.81, 138.91, 144.35, 145.35, 147.02, 150.55, 158.84, 165.11, 189.04 ppm.

(*E*)-Ethyl 6-methyl-2-(2-oxo-2-phenylethylidene)-4-phenyl-3-(2,4,6-triisopropylbenzoyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (4h) Yellow solid (119 mg, 81%); m.p. = 138~139 °C. ¹H NMR (400 MHz, CDCl₃): δ = 0.97 (d, *J* = 6.8 Hz, 3H), 1.06 (d, *J* = 6.8 Hz, 3H), 1.10 (d, *J* = 7.2 Hz, 3H), 1.13-1.20 (m, 9H), 1.27 (d, *J* = 6.8 Hz, 3H), 2.52 (s, 3H), 2.78-2.86 (m, 2H), 2.95-2.98 (m, 1H), 4.14 (q, *J* = 6.8 Hz, 2H), 5.15 (s, 1H), 6.85 (s, 1H), 6.95 (s, 1H), 7.03-7.28 (m, 11H), 12.78 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.08, 18.23, 22.73, 22.87, 23.72, 23.83, 24.08, 25.36, 25.42, 30.89, 31.34, 31.61, 34.29, 50.19, 60.29, 92.17, 105.89, 120.69, 121.38, 121.66, 126.15, 126.72, 126.93, 127.47, 127.86, 127.93, 128.53, 131.53, 131.73, 138.80, 139.14, 143.87, 144.53, 145.49, 149.92, 150.57, 165.14, 168.97, 189.38 ppm.

Ethyl 9-benzoyl-2-methyl-6-oxo-4-phenyl-4,6,7,8-tetrahydro-1H-pyrido[1,2-a]pyrimidinecarboxylate (6a) Yellow solid (82 mg, 79%), m.p. 222~223°C. ¹H NMR (400 MHz, CDCl₃): δ = 1.25 (t, *J* = 6.8Hz, 3H), 2.57 (s, 3H), 2.62 (d, 8.0Hz, 4H), 4.14-4.19 (m, 2H), 6.71 (s, 1H), 7.29-7.36 (m, 3H), 7.41-7.45 (m, 7H), 13.27 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): = 14.24, 18.86, 21.55, 33.42, 49.82, 60.36, 91.57, 104.36, 126.90, 127.25, 128.09, 128.20, 128.70, 130.08, 140.55, 140.62, 143.79, 149.62, 165.05, 168.80, 193.93 ppm.

Ethyl 9-benzoyl-4-(2-methoxyphenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6b) Yellow solid (80 mg, 72%), m.p. = $189 \sim 190^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): = 1.23 (t, *J* = 7.2Hz, 3H), 2.47 (d, *J* = 0.4Hz, 3H), 2.51-2.56 (m, 4H), 3.75 (s, 3H), 4.07-4.13 (m, 2H), 6.59 (s, 1H), 6.86-6.92 (m, 2H), 7.21-7.53 (m, 7H), 13.41 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.11$, 18.72, 21.49, 33.23, 49.81, 54.82, 59.99, 90.37, 111.05, 119.96, 126.76, 128.08, 129.20, 131.63, 132.38, 140.85, 142.42, 150.57, 157.85, 165.25, 168.83, 193.30 ppm.

Ethyl 9-benzoyl-4-(3-methoxyphenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6c) Yellow solid (83 mg, 75%), m.p. = $159 \sim 160$ °C. ¹H NMR (400 MHz, CDCl₃): = 1.24 (t, *J* = 7.2Hz, 3H), 2.54 (s, 3H), 2.57 - 2.62 (m, 4H), 3.78 (s, 3H), 4.13 - 4.19 (q, 2H), 6.68 (s, 1H), 6.82 (d, *J* = 8.0Hz, 1H), 6.96 - 6.99 (m, 2H), 7.22 - 7.27 (m, 1H), 7.40 (d, *J* = 3.6Hz, 5), 13.23 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.14, 18.73, 21.43, 33.31, 49.50, 55.07, 60.23, 91.45, 104.11, 113.01, 113.24, 119.24, 126.77, 128.06, 129.59, 129.94, 140.49, 141.87, 143.75, 149.48, 159.60, 164.92, 168.64, 193.76 ppm.

Ethyl 9-benzoyl-4-(4-methoxyphenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6d) Yellow solid (82 mg, 74%), m.p. = $153 \sim 154^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): δ = 1.23 (t, *J* = 7.2Hz, 3H), 2.55 (s, 3H), 2.59 (d, *J* = 6.8Hz, 4H), 3.78 (s, 3H), 4.12-4.17 (q, 2H), 6.63 (s, 1H), 6.84 (d, *J* = 8.4Hz, 1H), 7.33 (d, *J* = 8.4Hz, 2H), 7.36-7.42 (m, 5H), 13.26 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): = 14.13, 18.68, 21.45, 33.28, 49.25, 55.10, 60.19, 91.38, 104.51, 113.88, 126.77, 128.06, 128.48, 129.91, 132.68, 140.56, 143.36, 149.54, 159.24, 164.95, 168.67, 193.68 ppm.

Ethyl 9-benzoyl-2-methyl-4-(4-nitrophenyl)-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3carboxylate (6e) Red solid (62 mg, 54%), m.p. = $201 \sim 202^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): = 1.21 (t, *J* = 6.8Hz, 3H), 2.54 (s, 3H), 2.59 (m, 4H), 4.13 (q, 2H), 6.68 (s, 1H), 7.39 (q, 5H), 7.56 (d, *J* = 8.4Hz, 2H), 8.15 (d, *J* = 8.8Hz, 2H), 13.22 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.14, 18.90, 21.44, 33.07, 49.37, 60.50, 91.82, 102.91, 123.92, 126.78, 128.15, 128.27, 130.24, 140.20, 144.51, 147.45, 147.52, 148.58, 164.59, 168.59, 194.40 ppm.

Ethyl 9-benzoyl-4-(4-chlorophenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6f) Yellow solid (76 mg, 68%), m.p. = 229°C. ¹H NMR (400 MHz, CDCl₃): = 1.22 (t, *J* = 7.2Hz, 3H), 2.55 (s, 3H), 2.56-2.60 (m, 4H), 4.12-4.17 (q, 2H), 6.64 (s, 1H), 7.28 (d, *J* = 8.4Hz, 2H), 7.347.41 (m, 7H), 13.25 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.06$, 18.68, 21.35, 33.09, 49.11, 60.23, 91.49, 103.63, 126.71, 128.01, 128.62, 128.69, 129.98, 133.72, 138.90, 140.29, 143.82, 149.01, 164.67, 168.54, 193.89 ppm.

Ethyl 9-benzoyl-4-(2-chlorophenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6g) Yellow solid (102 mg, 91%), m.p. = 209~210°C. ¹H NMR (400 MHz, CDCl₃): = 1.22 (t, *J* = 6.8Hz, 3H), 2.53 (s, 3H), 2.54-2.57 (m, 4H), 4.10-4.15 (m, 2H), 6.86 (s, 1H), 7.19-7.24 (m, 2H), 7.34-7.50 (m, 7H), 13.39 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.22, 18.84, 21.47, 33.34, 49.29, 60.33, 91.78, 103.72, 126.92, 127.10, 128.18, 129.31, 130.10, 130.31, 130.53, 133.21, 138.78, 140.59, 143.03, 149.52, 164.91, 168.86, 194.07 ppm.

Ethyl 9-benzoyl-4-(4-(diethylamino)phenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido [1,2a]pyrimidine-3-carboxylate (6h) Yellow solid (85 mg, 70%), m.p. = $166 \sim 167^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): = 1.14 (t, *J* = 7.2Hz, 6H), 1.25 (t, *J* = 7.2Hz, 3H), 2.53 (s, 4H), 2.59-2.65 (m, 3H), 3.30-3.35 (q, 4H), 4.12-4.17 (q, 2H), 6.57-6.59 (m, 3H), 7.22 (d, *J* = 8.4Hz, 2H), 7.40 (d, *J* = 4.0Hz, 7H), 13.29 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 12.55, 14.18, 18.69, 21.50, 33.41, 44.16, 49.37, 60.15, 91.20, 105.06, 111.25, 126.81, 126.96, 128.05, 128.36, 129.80, 140.76, 142.88, 147.44, 150.00, 165.16, 168.74, 193.38 ppm.

Ethyl 9-benzoyl-2,7-dimethyl-6-oxo-4-phenyl-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6i) Yellow solid (80 mg, 75%), m.p. = $180 \sim 181^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): = $1.16 \cdot 1.25$ (m, 6H), 2.32-2.43 (m, 1H), 2.55 (s, 3H), 2.73-2.82 (m, 2H), 4.12-4.17 (q, 2H), 6.63 (d, *J* = 16.4Hz, 1H), 7.26-7.31 (m, 3H), 7.40 (s, 7H), 13.30 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.12, 15.32, 18.82, 28.12, 37.00, 50.11, 60.24, 88.55, 104.33, 126.72, 126.87, 127.16, 127.94, 128.09, 128.54, 129.78, 140.61, 140.68, 143.62, 148.72, 164.93, 171.97, 194.70 ppm.

Ethyl 9-benzoyl-4-(4-chlorophenyl)-2,7-dimethyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido [1,2a]pyrimidine-3-carboxylate (6j) Yellow solid (84 mg, 72%), m.p. = $170 \sim 171^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): = 1.15 - 1.25 (m, 6H), 2.35 (d, *J* = 15.2Hz, 1H), 2.56 (s, 1H), 2.72-2.81 (m, 2H), 4.12-4.17 (q, 2H), 6.58 (d, *J* = 14.4Hz, 2H), 7.27-7.43 (m, 7H), 13.26 (d, *J* = 15.2Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.12$, 15.29, 18.85, 28.10, 36.88, 49.59, 60.31, 88.67, 91.78, 103.78, 126.70, 128.11, 128.72, 129.87, 133.77, 139.10, 140.51, 143.83, 148.28, 148.88, 164.76, 171.91, 194.87 ppm.

Ethyl9-benzoyl-4-(2-chlorophenyl)-2,7-dimethyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a]pyrimidine-3-carboxylate (6k)Yellow solid (99 mg, 83%), m.p. = $192 \sim 193^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): = 1.12-1.25 (m, 6H), 2.33 (dd, J = 15.6, 2.8Hz, 1H), 2.53 (s, 3H), 2.67 (d, J = 4.8Hz, 1H), 2.76 (dd, J = 15.6, 5.4Hz, 1H), 4.11-4.14 (q, J = 7.2 Hz, 2H), 6.81 (d, J = 19.2Hz, 1H), 7.21 (s, 2H), 7.33-7.50 (m, 7H), 13.47 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.11, 15.30, 18.82, 28.10, 36.81, 49.65, 60.19, 88.70, 103.56, 126.70, 126.88, 126.98, 128.07, 129.13, 129.78, 130.01, 130.13, 130.33, 133.12, 138.87, 138.91, 140.64, 142.86, 148.62, 164.78, 172.03, 194.78 ppm.$

Ethyl 4-methyl-6-phenyl-2-(phenylethynyl)pyrimidine-5-carboxylate (8a): White solid (68 mg, 79%); m.p. = 161-162 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.70-7.66 (m, 4H), 7.48-7.39 (m, 3H), 7.38-7.27 (m, 3H), 4.22- 4.17 (q, *J* = 8.0 Hz, 2H), 2.67 (s, 3H), 1.06 (t, *J* = 8.0 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ = 167.53, 165.59, 164.08, 152.38, 137.19, 132.85, 132.54, 130.40, 130.01, 129.91, 129.52, 128.75, 126.53, 128.38, 128.17, 124.19, 121.25, 88.53, 88.09, 61.98, 22.47, 13.48 ppm.

Ethyl 4-Methyl-6-phenyl-2-(p-tolylethynyl)pyrimidine-5-carboxylate (8b): Yellow oil (73 mg, 81%). ¹H NMR (400 MHz, CDCl₃): δ = 7.65-7.56 (m, 2H), 7.51 (d, *J* = 8.0 Hz, 2H), 7.45-7.33 (m, 3H), 7.10 (d, *J* = 7.9 Hz, 2H), 4.12 (q, *J* = 7.2 Hz, 2H), 2.58 (s, 3H), 2.30 (s, 3H), 0.99 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ = 167.57, 165.54, 164.05, 152.47, 140.17, 137.20, 132.65, 130.16, 129.13, 128.54, 128.29, 124.00, 118.09, 89.07, 87.66, 61.96, 22.61, 21.63, 13.58 ppm.

Ethyl 4-Methyl-2-(oct-1-ynyl)-6-phenylpyrimidine-5-carboxylate (8c): Yellow oil (74 mg, 83%). ¹H NMR (400 MHz, CDCl3): δ = 7.63–7.49 (m, 2H), 7.47–7.28 (m, 3 H), 4.10 (q, *J* = 7.2 Hz, 2 H), 2.54 (s, 3 H), 2.40 (t, *J* = 7.3 Hz, 2 H), 1.65–1.53 (m, 2 H), 1.43–1.33 (m, 2 H),1.28–1.19 (m, 4 H), 0.97 (t, *J* = 7.2 Hz, 3 H), 0.81 (t, *J* = 6.7 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl3): δ = 167.58, 165.39, 163.91,152.27, 137.18, 130.06, 128.44, 128.25, 123.95, 91.65, 79.93, 61.87,31.25, 28.70, 27.89, 22.52, 22.43, 19.41, 13.99, 13.53 ppm.

Ethyl 2-(3,3-Dimethylbut-1-ynyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (8d): White solid (65 mg, 80%); m.p. = 98-99 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.57-7.36 (m, 2H), 7.46-7.25 (m, 3H), 4.10 (q, *J* = 7.2 Hz, 2H), 2.54 (s, 3H), 1.30 (s, 9H), 0.97 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ = 167.61, 165.29, 163.90, 152.51, 137.33, 129.99, 128.43, 128.29, 123.94, 98.45, 78.87, 61.82, 30.38, 27.90, 22.52, 13.54. ppm.

Ethyl 4-(4-Fluorophenyl)-6-methyl-2-(oct-1-ynyl)pyrimidine-5-carboxylate (8e): Yellow oil (70 mg, 76%). ¹H NMR (400 MHz, CDCl₃): δ = 7.64–7.51 (m, 2H), 7.04 (dd, *J* = 11.9, 5.3 Hz, 2H), 3.71–3.55 (m, 3H), 2.39 (t, *J* = 7.3 Hz, 2H), 1.67–1.50 (m, 2H), 1.41–1.32 (m, 2H), 1.23 (t, *J* = 6.9 Hz, 9H), 0.80 (d, *J* = 1.2 Hz, 3H) ppm. ¹³C NMR(100 MHz, CDCl₃): δ = 173.16, 168.23, 165.03, 162.54, 162.20,152.74, 133.33, 130.29, 130.21, 122.79, 115.67, 115.66, 115.44,90.99, 80.23, 52.56, 33.35, 31.14, 28.60, 27.83, 22.33, 21.45, 19.37,13.86 ppm.

Ethyl 4-(4-Chlorophenyl)-6-methyl-2-(oct-1-ynyl)pyrimidine-5-carboxylate (8f): Yellow oil (80 mg, 84%). ¹H NMR (400 MHz, CDCl₃): δ = 7.58–7.45 (m, 2H), 7.42–7.31 (m, 2H), 4.11–4.17 (m, 2H), 2.54 (d, J = 1.2 Hz, 3H), 2.40 (t, J = 7.3 Hz, 2H), 1.65–1.54 (m, 2H), 1.43–1.34 (m, 2H), 1.28–1.19 (m, 4H), 1.07–1.03 (m, 3H), 0.85–0.76(m, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 167.43, 165.64,162.59, 152.33, 136.52, 135.59, 129.73, 128.75, 123.84, 92.04, 79.86,62.07, 31.27, 29.65, 28.72, 27.90, 22.56, 22.45, 19.44, 14.01,13.67 ppm.

Ethyl 4-Methyl-2-(oct-1-ynyl)-6-p-tolylpyrimidine-5-carboxylate (8g): Yellow oil (70 mg, 77%). ¹H NMR (400 MHz, CDCl₃): δ = 7.48 (dd, *J* =8.2, 2.0 Hz, 2 H), 7.18–7.14 (m, 2H), 4.13 (dd, *J* = 7.2, 2.9 Hz, 2H), 2.52 (d, *J* = 2.5 Hz, 3 H), 2.42–2.37 (m, 2H), 2.31 (d, *J* =2.6 Hz, 3H), 1.64–1.54 (m, 2 H), 1.38 (dd, *J* = 13.1, 6.4 Hz, 2H),1.28–1.16 (m, 4H), 1.05–1.01 (m, 3H), 0.82–0.79 (m, 3 H) ppm.¹³C NMR (100 MHz, CDCl₃): δ = 167.83, 165.15, 163.72, 152.25,140.42, 134.27, 129.17, 128.28, 123.80, 91.41, 80.03, 61.86, 31.27,28.71, 27.92, 22.50, 22.45, 21.35, 19.43, 14.00, 13.64 ppm.

Ethyl 6-methyl-2,4-diphenyl-1,4-dihydropyrimidine-5-carboxylate (10a) Yellow oil (52 mg, 65%). ¹H NMR (400 MHz, CDCl₃): $\delta = 1.16$ (t, J = 5.6 Hz, 3H), 2.41 (s, 3H), 4.05-4.06 (m, 2H), 5.68 (s, 1H), 7.18-7.26 (m, 3H), 7.33 (d, J = 6.8 Hz, 2H), 7.41 (d, J = 7.2 Hz, 2H), 7.52-7.57 (m, 3H), 7.63 (d, J = 7.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.10$, 29.49, 56.96, 59.44, 101.16, 126.93, 126.97, 128.12, 128.28, 128.40, 130.54, 131.71, 131.81, 132.49, 133.56, 145.27, 166.76 ppm.

Ethyl 4-(2-methoxyphenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10b) Yellow oil (41 mg, 47%). ¹H NMR (400 MHz, CDCl₃): $\delta = 1.14$ (t, J = 5.6 Hz, 3H), 2.38 (s, 3H), 3.71 (s, 3H), 4.04 ((q, J = 5.6 Hz, 2H), 5.61 (s, 1H), 7.20-7.64 (m, 10H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.10$, 29.49, 56.96, 58.10, 60.04, 105.15, 111.12, 126.73, 126.97, 127.92, 128.28, 128.42, 130.51, 131.53, 132.01, 132.49, 133.36, 146.27, 165.76 ppm.

Ethyl 4-(3-methoxyphenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10c) Yellow oil (44 mg, 51%). ¹H NMR (400 MHz, CDCl₃): $\delta = 1.14$ (t, J = 5.6 Hz, 3H), 2.38 (s, 3H), 3.71 (s, 3H), 4.04 (q, J = 5.6 Hz, 2H), 5.60 (s, 1H), 7.04-7.60 (m, 10H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.11$, 29.46, 56.86, 58.12, 60.09, 105.25, 111.82, 126.03, 126.91, 127.22, 128.68, 128.92, 130.41, 131.73, 132.51,

132.79, 133.46, 146.07, 165.86 ppm.

Ethyl 4-(4-methoxyphenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10d) Yellow oil (50 mg, 57%). ¹H NMR (400 MHz, CDCl₃): $\delta = 1.15$ (t, J = 5.6 Hz, 3H), 2.38 (s, 3H), 3.71 (s, 3H), 4.05 (q, J = 5.6 Hz, 2H), 5.61 (s, 1H), 7.16-7.57 (m, 10H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.04$, 29.59, 56.90, 58.30, 59.95, 104.95, 112.02, 126.43, 126.87, 127.90, 128.29, 128.48, 130.53, 131.57, 132.09, 132.43, 133.39, 146.24, 165.79 ppm.

Ethyl 4-(2-chlorophenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10e) Yellow oil (61 mg, 69%). ¹H NMR (400 MHz, CDCl₃): δ = 1.16 (t, *J* = 5.6 Hz, 3H), 2.31 (s, 3H), 4.07 (q, *J* = 5.6 Hz, 2H), 5.91 (s, 1H), 7.17-7.73 (m, 10H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.10, 29.69, 56.96, 60.44, 107.15, 127.13, 128.12, 128.58, 129.40, 130.53, 131.67, 132.81, 135.49, 143.57, 150.27, 155.77, 167.38 ppm.

Ethyl 4-(4-chlorophenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10f) Yellow oil (54 mg, 61%). ¹H NMR (400 MHz, CDCl₃): δ = 1.16 (t, *J* = 5.6 Hz, 3H), 2.12 (s, 3H), 4.06 (q, *J* = 5.6 Hz, 2H), 5.82 (s, 1H), 7.27-7.76 (m, 10H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.12, 29.79, 54.93, 60.14, 107.35, 128.13, 128.42, 128.57, 129.10, 130.83, 132.11, 135.59, 143.07, 150.10, 156.38, 167.68 ppm.

Ethyl 6-methyl-4-phenyl-2-o-tolyl-1,4-dihydropyrimidine-5-carboxylate (10g) Yellow oil (43 mg, 52%). ¹H NMR (400 MHz, CDCl₃): δ = 1.16 (t, *J* = 5.6 Hz, 3H), 2.22 (s, 3H), 2.26 (s, 3H), 4.04 (q, *J* = 5.6 Hz, 2H), 5.68 (s, 1H), 7.18-7.53 (m, 10H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.10, 20.26, 29.49, 54.96, 60.44, 104.16, 125.93, 126.93, 127.92, 128.26, 128.50, 129.68, 130.94, 134.71, 136.81, 143.46, 149.56, 155.26, 166.67 ppm.

Ethyl 4-methyl-2,6-diphenylpyrimidine-5-carboxylate (11a): White solid (66 mg, 82%); m.p. = 66-67 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.62- 8.59 (dd, *J* = 2.8 Hz, 6.4 Hz, 2H), 7.81-7.79 (m, 2H), 7.54-7.52 (m, 6H), 4.28-4.22 (q, *J* = 7.2 Hz, 2H), 2.75 (s, 3H), 1.14-1.10 (t, J= 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ= 168.5, 165.4, 163.7, 163.7, 138.2, 137.1, 131.1, 130.0, 128.7, 128.6, 128.5, 128.5, 123.4, 61.8, 22.9, 13.7 ppm.

Ethyl 4-(4-fluorophenyl)-6-methyl-2-phenylpyrimidine-5-carboxylate (11b): White solid (65 mg, 78%); m.p. = 85- 86 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.46 (dd, *J* = 6.8, 3.0 Hz, 2H), 7.77-7.62 (m, 2H), 7.48-7.33 (m, 3H), 7.11-7.06 (m, 2H), 4.16 (q, *J* = 7.2 Hz, 2H), 2.61 (s, 3H), 1.06 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.33, 165.46, 165.20, 163.65, 162.71, 162.28, 136.97, 134.28, 131.10, 130.58, 130.50, 128.58, 128.50, 123.16, 115.66, 115.44, 61.84, 22.82, 13.74 ppm.

Ethyl 4-(4-chlorophenyl)-6-methyl-2-phenylpyrimidine-5-carboxylate (11c): White solid (78 mg, 87%); m.p. = 83-84 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.52-8.41 (m, 2H), 7.69-7.59 (m, 2H), 7.47-7.34 (m, 5H), 4.16 (q, *J* = 7.2 Hz, 2H), 2.62 (s, 3H), 1.07 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.15, 165.55, 163.66, 162.31, 136.81, 136.56, 136.36, 131.20, 129.85, 128.73, 128.63, 128.52, 123.19, 61.92, 22.79, 13.74 ppm.

Ethyl 4-(4-bromophenyl)-6-methyl-2-phenylpyrimidine-5-carboxylate (11d): White solid (78 mg, 89%); m.p. = 87-89 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.50 (m, 2H), 7.78 (d, *J* = 8.4 Hz, 2H), 7.47-7.37 (m, 5H), 4.19 (q, *J* = 7.2 Hz, 2H), 2.63 (s, 3H), 1.06 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.52, 165.39, 163.06, 137.14, 137.00, 131.02, 128.94, 128.87, 128.60, 128.49, 127.78, 127.18, 127.16, 123.22, 61.82, 22.88, 13.72 ppm.

Ethyl 4-methyl-2-phenyl-6-p-tolylpyrimidine-5-carboxylate (11e): White solid (70 mg, 84%); m.p. 66-67 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.60-8.38 (m, 2H), 7.60 (d, *J* = 8.1 Hz, 2H), 7.46-7.35 (m, 3H), 7.23-7.17 (m, 2H), 4.16 (q, *J* = 7.2 Hz, 2H), 2.60 (s, 3H), 2.34 (s, 3H), 1.06 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.63, 165.14, 163.59, 163.34, 140.23, 137.23, 135.30, 130.91, 129.17,

128.58, 128.44, 128.41, 123.14, 61.72, 22.81, 21.38, 13.73 ppm.

Ethyl 4-methyl-6-phenyl-2-o-tolylpyrimidine-5-carboxylate (11f): White solid (53 mg, 64%); m.p. = 77-78 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.87-7.79 (m, 1H), 7.73-7.57 (m, 2H), 7.46-7.33 (m, 3H), 7.32-7.19 (m, 3H), 4.16 (q, *J* = 7.2 Hz, 2H), 2.63 (s, 3H), 2.55 (s, 3H), 1.03 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.36, 166.75, 165.00, 163.12, 137.93, 137.62, 137.45, 131.31, 130.55, 129.97, 129.65, 128.48, 128.39, 125.93, 122.77, 61.86, 22.78, 21.32, 13.66 ppm.

Ethyl 4-methyl-6-phenyl-2-m-tolylpyrimidine-5-carboxylate (11g): White solid (71 mg, 83%); m.p. = 69-71 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.27- 8.29 (d, *J* = 7.4 Hz, 2H), 7.69-7.67 (dd, *J* = 6.5 Hz, 3.1 Hz, 2H), 7.42-7.39 (m, 3H), 7.33-7.29(t, *J* = 7.9 Hz, 1H), 7.25-7.23(t, *J* = 7.5 Hz, 1H), 4.16-4.11 (q, *J* = 7.2 Hz, 2H), 2.62 (s, 3H), 2.38 (s, 3H), 1.02-0.99 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.4, 165.3, 163.8, 163.3, 138.2, 138.1, 137.0, 131.8, 129.9, 129.1, 128.5, 128.4, 125.8, 123.3, 61.7, 22.9, 21.5, 13.6 ppm.

Ethyl 4-methyl-6-phenyl-2-p-tolylpyrimidine-5-carboxylate (11h): White solid (70 mg, 85%); m.p. = 61-63 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.49-8.47 (d, *J* = 8.2 Hz, 2H), 7.79-7.77 (m, 2H), 7.54-7.46 (m, 3H), 7.33-7.31 (d, *J* = 8.1 Hz, 3H), 4.26-4.21 (q, *J* = 7.2 Hz, 2H), 2.72 (s, 3H), 2.46 (s, 3H), 1.12-1.10 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.5, 165.3, 163.7, 163.6, 141.5, 138.3, 134.4, 130.0, 129.3, 128.7, 128.5, 128.5, 123.1, 61.8, 22.7, 21.6, 13.7 ppm.

Ethyl 2-(4-methoxyphenyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (11i): White solid (32 mg, 91%); m.p. = 57-59 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.49-8.39 (m, 2H), 7.72-7.60 (m, 2H), 7.46-7.32 (m, 3H), 6.95-6.85 (m, 2H), 4.11 (q, *J* = 7.2 Hz, 2H), 3.79 (s, 3H), 2.59 (s, 3H), 0.99 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.54, 165.23, 163.53, 163.40, 162.13, 141.51, 138.41, 134.4, 130.34, 129.82, 128.39, 122.57, 113.79, 61.63, 55.33, 22.84, 13.63 ppm.

Ethyl 2-(4-chlorophenyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (11j): White solid (75 mg, 85%); m.p. = 84-86 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.51-8.36 (m, 2H), 7.80-7.56 (m, 2H), 7.52-7.29 (m, 5H), 4.13 (q, *J* = 7.2 Hz, 2H), 2.61 (s, 3H), 1.01 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.25, 165.48, 163.63, 162.64, 138.04, 137.29, 135.59, 130.00, 129.96, 128.70, 128.44, 128.41, 123.52, 61.80, 22.80, 13.64 ppm.

Ethyl 4-methyl-2-(naphthalen-1-yl)-6-phenylpyrimidine-5-carboxylate (11k): White solid (68 mg, 73%); m.p. = 83-85 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.62-8.60 (m, 1H), 8.06 (dd, *J* = 7.2, 1.2 Hz, 1H), 7.89 (d, *J* = 8.2 Hz, 1H), 7.87-7.80 (m, 1H), 7.77-7.65 (m, 2H), 7.59-7.31 (m, 6H), 4.18 (q, *J* = 7.2 Hz, 2H), 2.69 (s, 3H), 1.05 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 168.26, 166.35, 165.29, 163.53, 137.85, 135.41, 134.05, 130.96, 130.73, 130.06, 129.58, 128.55, 128.42, 126.85, 125.85, 125.70, 125.16, 123.18, 109.69, 61.93, 22.86, 13.67 ppm.

Ethyl 4-methyl-6-phenyl-2-(thiophen-2-yl)pyrimidine-5-carboxylate (111): White solid (55 mg, 69%); m.p. = 89-91 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.03 (dd, *J* = 3.7, 1.1 Hz, 1H), 7.71-7.56 (m, 2H), 7.51-7.28 (m, 4H), 7.07 (dd, *J* = 4.9, 3.8Hz, 1H), 4.11 (q, *J* = 7.2 Hz, 2H), 2.57 (s, 3H), 0.99 (t, *J* = 7.2 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ = 168.20, 165.54,163.67, 160.49, 142.96, 137.88, 130.54, 130.00, 129.82, 128.42, 128.29, 128.21, 122.77, 61.71, 22.70, 13.61 ppm.

(*E*)-ethyl 3-acetyl-6-methyl-2-(2-oxo-2-phenylethylidene)-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (4a)



(*E*)-ethyl 3-acetyl-4-(2-methoxyphenyl)-6-methyl-2-(2-oxo-2-phenylethylidene)-1,2,3,4tetrahydropyrimidine-5-carboxylate (4b)



(*E*)-ethyl 3-acetyl-6-methyl-4-(4-nitrophenyl)-2-(2-oxo-2-phenylethylidene)-1,2,3,4tetrahydropyrimidine-5-carboxylate (4c)



(E)-ethyl 3-acetyl-4-(2-chlorophenyl)-6-methyl-2-(2-oxo-2-phenylethylidene)-1,2,3,4tetrahydropyrimidine-5-carboxylate (4d)



(*E*)-ethyl 3-hexanoyl-6-methyl-2-(2-oxohexylidene)-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (4e)



(E)-ethyl 6-methyl-2-(2-oxo-2-phenylethylidene)-4-phenyl-3-(thiophene-2-carbonyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (4f)



(E)-ethyl 3-(furan-2-carbonyl)-6-methyl-2-(2-oxo-2-phenylethylidene)-4-phenyl-1,2,3,4tetrahydropyrimidine-5-carboxylate (4g)



(*E*)-ethyl 6-methyl-2-(2-oxo-2-phenylethylidene)-4-phenyl-3-(2,4,6-triisopropylbenzoyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (4h)



Ethyl 9-benzoyl-2-methyl-6-oxo-4-phenyl-4,6,7,8-tetrahydro-1H-pyrido[1,2a]pyrimidine- 3-carboxylate (6a)



-13.405 1.257 ---0.000 -1100 -1000 0 ð H₃C -900 0 Ì H₃C -800 ſ 0 -700 -600 -500 -400 -300 -200 -100 -0 0.97-1 2.07-3.97 3.21-2.99→ -100 -1 13 12 11 10 3 2 0 -2 9 6 f1 (ppm) 5 4 8 -11000 132.53 131.63 123.26 131.65 132.63 133.65 133.65 133.65 -193.30 -157.85 ~142.42 ~140.85 -150.57 -111.05 ₹75.30 ₹76.98 76.66 54.82 49.81 -33.23 ~21.49 ~18.72 ~14.11 -90.37 -16000 -15000 -14000 -13000 -12000 -11000 -10000 -9000 -8000 -7000 -6000 -5000 4000 -3000 -2000 1000 0 -1000

Ethyl 9-benzoyl-4-(2-methoxyphenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6b)

80

60

50 40

70

170 160 150 140 130 120 110 100 90 fl (ppm)

230 220 210 200 190

180

--2000

0

-10

30

20 10

-13.225 7, 400 7, 255 7, 255 7, 255 7, 255 7, 255 7, 255 7, 255 6, 961 6, 961 6, 961 6, 677 6, 961 6, 677 6, 961 2.620 2.571 2.571 2.571 $\underbrace{}_{1.261}^{1.261}$ -850 CH3 20 -800 0 -750 -700 H₃C õ 1/11 -650 H₃C -600 0 -550 -500 -450 -400 -350 -300 -250 -200 -150 -100 -50 -0 588538 2.08-1 3.97 1.01-3.05---50 2 3 -1 4 13 12 10 0 11 9 7 6 f1 (ppm) 5 1 4 8 Z129.99 728.99 7128.06 -119.24 -119.24 ~168.64 ~164.92 ~159.60 -104.11 -193.76 ---91.45 ₹78.99 76.67 ---60.23 ---55.07 ---49.50 -33.31 ~21.43 ~18.73 ~14.14 -18000 -17000 -16000 -15000 -14000 -13000 -12000 -11000 -10000 -9000 -8000 -7000 -6000 -5000 -4000 -3000 -2000 1000 0 -1000 --2000 170 160 150 140 130 120 110 100 90 f1 (ppm) 0 -10 230 220 210 200 80 60 40 30 20 10 70 50 190 180

Ethyl 9-benzoyl-4-(3-methoxyphenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6c)

Ethyl 9-benzoyl-4-(4-methoxyphenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6d)



Ethyl 9-benzoyl-2-methyl-4-(4-nitrophenyl)-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6e)



Ethyl 9-benzoyl-4-(4-chlorophenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6f)



Ethyl 9-benzoyl-4-(2-chlorophenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6g)



Ethyl 9-benzoyl-4-(4-(diethylamino)phenyl)-2-methyl-6-oxo-4,6,7,8-tetrahydro-1Hpyrido [1,2-a]pyrimidine-3-carboxylate (6h)



Ethyl 9-benzoyl-2,7-dimethyl-6-oxo-4-phenyl-4,6,7,8-tetrahydro-1H-pyrido[1,2-a] pyrimidine-3-carboxylate (6i)



Ethyl 9-benzoyl-4-(4-chlorophenyl)-2,7-dimethyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido [1,2-a]pyrimidine-3-carboxylate (6j)



Ethyl 9-benzoyl-4-(2-chlorophenyl)-2,7-dimethyl-6-oxo-4,6,7,8-tetrahydro-1H-pyrido [1,2-a]pyrimidine-3-carboxylate (6k)





Ethyl 4-methyl-6-phenyl-2-(phenylethynyl)pyrimidine-5-carboxylate (8a)



Ethyl 4-Methyl-6-phenyl-2-(p-tolylethynyl)pyrimidine-5-carboxylate (8b)



Ethyl 4-Methyl-2-(oct-1-ynyl)-6-phenylpyrimidine-5-carboxylate (8c)



Ethyl 2-(3,3-Dimethylbut-1-ynyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (8d)



Ethyl 4-(4-Fluorophenyl)-6-methyl-2-(oct-1-ynyl)pyrimidine-5-carboxylate (8e)



Ethyl 4-(4-Chlorophenyl)-6-methyl-2-(oct-1-ynyl)pyrimidine-5-carboxylate (8f)



Ethyl 4-Methyl-2-(oct-1-ynyl)-6-p-tolylpyrimidine-5-carboxylate (8g)



Ethyl 6-methyl-2,4-diphenyl-1,4-dihydropyrimidine-5-carboxylate (10a)



Ethyl 4-(2-methoxyphenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10b)

Ethyl 4-(3-methoxyphenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10c)



Ethyl 4-(4-methoxyphenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10d)



Ethyl 4-(2-chlorophenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10e)



Ethyl 4-(4-chlorophenyl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxylate (10f)



Ethyl 6-methyl-4-phenyl-2-o-tolyl-1,4-dihydropyrimidine-5-carboxylate (10g)



Ethyl 4-methyl-2,6-diphenylpyrimidine-5-carboxylate (11a)



Ethyl 4-(4-fluorophenyl)-6-methyl-2-phenylpyrimidine-5-carboxylate (11b)



Ethyl 4-(4-chlorophenyl)-6-methyl-2-phenylpyrimidine-5-carboxylate (11c)



Ethyl 4-(4-bromophenyl)-6-methyl-2-phenylpyrimidine-5-carboxylate (11d)



Ethyl 4-methyl-2-phenyl-6-p-tolylpyrimidine-5-carboxylate (11e)



Ethyl 4-methyl-6-phenyl-2-o-tolylpyrimidine-5-carboxylate (11f)



Ethyl 4-methyl-6-phenyl-2-m-tolylpyrimidine-5-carboxylate (11g)



Ethyl 4-methyl-6-phenyl-2-p-tolylpyrimidine-5-carboxylate (11h)



Ethyl 2-(4-methoxyphenyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (11i)



Ethyl 2-(4-chlorophenyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (11j)



Ethyl 4-methyl-2-(naphthalen-1-yl)-6-phenylpyrimidine-5-carboxylate (11k)



Ethyl 4-methyl-6-phenyl-2-(thiophen-2-yl)pyrimidine-5-carboxylate (111)

